This Article Full Text Full Text (PDF) All Versions of this Article: 46/3/547    most recent 01.HYP.0000178572.63064.73v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, Q. Articles by Burnier, M. Search for Related Content PubMed PubMed Citation Articles by Wang, Q. Articles by Burnier, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB POTASSIUM SODIUM CHLORIDE Related Collections Cardio-renal physiology/pathophysiology Contractile function Hypertrophy Carotid Stenosis Related Article

(Hypertension. 2005;46:547.)
© 2005 American Heart Association, Inc.

Original Articles

Potassium Supplementation Reduces Cardiac and Renal Hypertrophy Independent of Blood Pressure in DOCA/Salt Mice

Qing Wang; Andrea A. Domenighetti; Thierry Pedrazzini; Michel Burnier

From the Division of Nephrology (Q.W., M.B.) and the Department of Medicine (A.A.D., T.P.), University Hospital, Lausanne, Switzerland.

Correspondence to Prof Michel Burnier, Division of Nephrology, CHUV, rue du Bugnon 17, CH-1011 Lausanne, Switzerland. E-mail michel.burnier{at}chuv.ch

We have demonstrated previously that deoxycorticosterone acetate (DOCA)/salt induces cardiac hypertrophy and left ventricular dysfunction independent of blood pressure (BP) in 1–renin gene mice. Because these mice also develop hypokalemia and metabolic alkalosis caused by mineralocorticoid excess, we investigated whether correcting hypokalemia by dietary potassium supplementation would prevent the DOCA/salt-induced cardiac hypertrophy, cardiac dysfunction, and electrocardiographic changes in normotensive, 1–renin gene and hypertensive, 2–renin gene mice. All mice were studied after 5 weeks of DOCA and salt administration. Potassium was given by adding 0.4 or 0.6% KCl to the drinking water. Our results show that correction of hypokalemia and metabolic alkalosis prevents cardiac hypertrophy and normalizes cardiac function without affecting BP in normotensive, 1–renin gene mice. In hypertensive, 2–renin gene mice, potassium supplementation induces a significant decrease in BP. The decrease in BP and correction of kalemia are associated with a significant but partial correction of cardiac hypertrophy. In both group of mice, electrocardiographic alterations were measured after administration of DOCA/salt, which could be corrected by potassium supplementation. Thus, these results show that correction of hypokalemia and metabolic alkalosis does prevent the development of cardiac hypertrophy and normalizes cardiac function independent of BP in normotensive, 1–renin gene mice that receive excess mineralocorticoid and salt. In 2–renin gene, hypertensive mice, potassium supplementation also prevents the development of cardiac hypertrophy, but the effect cannot be separated from the decrease in BP.

Key Words: hypokalemia • metabolism • hypertrophy • heart failure • deoxycorticosterone • mouse

Related Article:

Potassium Depletion and Cardiac Hypertrophy: How Does It Work?

Joseph I. Shapiro
Hypertension 2005 46: 477-478. [Full Text] [PDF]

This article has been cited by other articles:

				A. Karatas, B. Hegner, L. J. de Windt, F. C. Luft, C. Schubert, V. Gross, Y. J. Akashi, D. Gurgen, U. Kintscher, A. C. da Costa Goncalves, et al. Deoxycorticosterone Acetate-Salt Mice Exhibit Blood Pressure-Independent Sexual Dimorphism Hypertension, April 1, 2008; 51(4): 1177 - 1183. [Abstract] [Full Text] [PDF]

				C. S. Rigsby, A. E. Burch, S. Ogbi, D. M. Pollock, and A. M. Dorrance Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1754 - R1763. [Abstract] [Full Text] [PDF]

				W. Wang, L. Soltero, P. Zhang, X. R. Huang, H. Y. Lan, and H. J. Adrogue Renal inflammation is modulated by potassium in chronic kidney disease: possible role of Smad7 Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1123 - F1130. [Abstract] [Full Text] [PDF]

				S. N. Orlov and A. A. Mongin Salt-sensing mechanisms in blood pressure regulation and hypertension Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2039 - H2053. [Abstract] [Full Text] [PDF]

				M. Burnier, O. Phan, and Q. Wang High salt intake: a cause of blood pressure-independent left ventricular hypertrophy? Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2426 - 2429. [Full Text] [PDF]

				H. J. Adrogue and N. E. Madias Sodium and Potassium in the Pathogenesis of Hypertension N. Engl. J. Med., May 10, 2007; 356(19): 1966 - 1978. [Full Text] [PDF]

				B. Gavillet, J.-S. Rougier, A. A. Domenighetti, R. Behar, C. Boixel, P. Ruchat, H.-A. Lehr, T. Pedrazzini, and H. Abriel Cardiac Sodium Channel Nav1.5 Is Regulated by a Multiprotein Complex Composed of Syntrophins and Dystrophin Circ. Res., August 18, 2006; 99(4): 407 - 414. [Abstract] [Full Text] [PDF]

				H. Matsui, T. Shimosawa, Y. Uetake, H. Wang, S. Ogura, T. Kaneko, J. Liu, K. Ando, and T. Fujita Protective Effect of Potassium Against the Hypertensive Cardiac Dysfunction: Association With Reactive Oxygen Species Reduction Hypertension, August 1, 2006; 48(2): 225 - 231. [Abstract] [Full Text] [PDF]

				J. I. Shapiro Potassium Depletion and Cardiac Hypertrophy: How Does It Work? Hypertension, September 1, 2005; 46(3): 477 - 478. [Full Text] [PDF]